Intervention not reported
CIN2+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention leads to lower CIN2+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
CIN3+ associated with HPV16/18 (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention leads to lower CIN3+ associated with HPV16/18 (age 15 to 26 years) (high certainty).
1 finding from 1 review
Intervention not reported
AIS associated with HPV16/18 or 6/11/16/18 (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention probably leads to lower AIS associated with HPV16/18 or 6/11/16/18 (age 15 to 26 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention leads to lower any CIN2+ irrespective of HPV type (age 15 to 26 years) (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Any AIS irrespective of HPV type ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
CIN2+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower CIN2+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
CIN3+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower CIN3+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
CIN2+ associated with HPV16/18. · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower CIN2+ associated with HPV16/18. (high certainty).
1 finding from 1 review
Intervention not reported
Adeno carcinoma in situ (AIS) associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower adeno carcinoma in situ (AIS) associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower any CIN2+ irrespective of HPV type (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention probably leads to lower any CIN3+ irrespective of HPV type (age 15 to 26 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type (age 15 to 26 years), · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower any CIN3+ irrespective of HPV type (age 15 to 26 years), (high certainty).
1 finding from 1 review
Intervention not reported
Any AIS irrespective of HPV type (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower any AIS irrespective of HPV type (age 15 to 26 years) (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention showed no clear difference in serious adverse events (high certainty).
1 finding from 1 review
Intervention not reported
Deaths · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention showed no clear difference in deaths (low certainty).
1 finding from 1 review
Intervention not reported
Spontaneous abortion/miscarriage · adolescent girls and women aged 15 to 45 years who became pregnant during the study
The intervention showed no clear difference in spontaneous abortion/miscarriage (high certainty).
1 finding from 1 review
Intervention not reported
Elective termination/induced abortion · adolescent girls and women aged 15 to 45 years who became pregnant during the study
The intervention showed no clear difference in elective termination/induced abortion (high certainty).
1 finding from 1 review
Intervention not reported
Stillbirth · adolescent girls and women aged 15 to 45 years who became pregnant during the study
The intervention showed no clear difference in stillbirth (moderate certainty).
1 finding from 1 review